Biosig Technologies Inc represents values of innovation, quality, and integrity. The company is dedicated to developing and commercializing advanced biomedical signal processing platforms. Biosig Technologies Inc focuses on improving patient outcomes and providing cutting-edge solutions to the medical field. With a commitment to excellence, the company invests in research and development to develop innovative medical technologies. Biosig Technologies Inc's corporate philosophy emphasizes collaboration, transparency, and ethical practices in all its operations. The company's dedication to improving healthcare and delivering value to stakeholders is reflected in its continual advancements and contributions to the industry.

Biosig Technologies Inc is primarily present in the United States.

Biosig Technologies Inc has achieved significant milestones in its industry. Some notable achievements include the development and commercialization of its proprietary medical device, the PURE EP System. The company has also made significant progress in securing regulatory clearances, such as the FDA approval for the PURE EP System in 2018. Biosig Technologies Inc continues to advance its research and development efforts, fostering innovation and expanding its presence in the healthcare sector. With a strong commitment to improving patient care and outcomes, Biosig Technologies Inc is dedicated to revolutionizing electrophysiology and making a positive impact in the medical field.

Biosig Technologies Inc, a leading medical technology company, was founded in 2009. The company specializes in developing innovative biomedical signal processing solutions. With a focus on improving patient outcomes, Biosig Technologies has developed an advanced signal processing platform called the Pure EP System. This cutting-edge system is designed to enhance the accuracy and effectiveness of electrophysiology procedures, particularly for cardiac arrhythmia treatments. Through extensive research and development, Biosig Technologies is dedicated to providing healthcare professionals with state-of-the-art tools for precise diagnosis and treatment planning. As a result, Biosig Technologies Inc has gained a strong reputation as a trusted provider of advanced medical technologies in the market.

The main competitors of Biosig Technologies Inc in the market include Abiomed Inc, Medtronic plc, Boston Scientific Corporation, and Edwards Lifesciences Corporation.

Biosig Technologies Inc is primarily active in the healthcare and medical device industry.

The business model of Biosig Technologies Inc revolves around the development and commercialization of innovative biomedical devices. The company focuses on the design, manufacturing, and distribution of advanced signal processing platforms for the healthcare industry. Biosig Technologies specializes in developing products that enhance the analysis and monitoring of physiological signals for improved disease diagnosis and therapy. With a strong emphasis on research and development, as well as strategic partnerships, Biosig Technologies aims to provide cutting-edge solutions that address critical medical needs and contribute to the advancement of patient care.

BioSig Technologies KGV ir -0,35.

BioSig Technologies KUV ir 0.

AlleAktien kvalitātes vērtējums BioSig Technologies ir 5/10.

Pašreiz nevar aprēķināt apgrozījumu BioSig Technologies.

gaidāmā BioSig Technologies peļņa ir -8,79 milj. USD.

Biosig Technologies Inc. is a rising company that focuses on the development of medical devices and systems for cardiovascular diseases and neurological disorders. It was founded in 1998 and is headquartered in Westport, Connecticut. The company's core business revolves around researching, developing, manufacturing, and marketing medical devices and systems for the diagnosis and treatment of cardiovascular diseases and neurological disorders. They are a leading provider of innovative solutions that improve accuracy and effectiveness in patient diagnosis and treatment. Their main areas of expertise are electrophysiological systems for cardiovascular applications and technology platforms for neurological applications. They emphasize partnerships with other companies and research institutions to develop innovative solutions. Their current products include the PURE EP System for diagnosing and treating complex cardiac arrhythmias, and the NeurECG System for recording and analyzing electrophysiological signals from the brain for diagnosing and treating neurological disorders. In summary, Biosig Technologies specializes in developing and marketing medical devices and systems, and has established itself as a leading provider in the field of cardiovascular and neurological diagnostics and treatments through their innovative products and collaboration with other industry and research partners.

BioSig Technologies izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt BioSig Technologies vai uzņēmums nedod dividendes.

BioSig Technologies ISIN ir US09073N2018.

BioSig Technologies WKN ir A2N5TW.

BioSig Technologies simbols ir BSGM.

Pēdējo 12 mēnešu laikā BioSig Technologies maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos BioSig Technologies plāno maksāt dividendes 0 USD apmērā.

BioSig Technologies pašreizējā dividendu rentabilitāte ir .

BioSig Technologies maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

BioSig Technologies pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

BioSig Technologies tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu BioSig Technologies apmērā 0 USD, kas tika izmaksāta 1.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 1.08.2024..

Pēdējās dividendes izmaksa notika 1.08.2024..

Gadā 2023, BioSig Technologies izmaksāja 0 USD dividendes.

BioSig Technologies dividendes tiek izmaksātas USD.